The results also provided a potential strategy of blocking other immune checkpoints for early-stage TNBC, including anti-CTLA-4 reagents, which are currently being used in mouse experiments and clinical trials for advanced BC (10, 67, 68). This evidence concerns the gene CTLA4 and breast cancer.